Iterum Therapeutics Plc (ITRM)

May 19, 2025

Pfizer grants Iterum payment extension for FDA-approved antibiotic By Investing.com - Investing.com South Africa

May 19, 2025

May 19, 2025

Pfizer grants Iterum payment extension for FDA-approved antibiotic - Investing.com Australia

May 19, 2025

May 19, 2025

Iterum Therapeutics (ITRM) Extends $20M Payment Deadline with Pf - GuruFocus

May 19, 2025

May 19, 2025

Iterum Therapeutics Announces Extension of Term of Promissory No - GuruFocus

May 19, 2025

May 19, 2025

Iterum Therapeutics Announces Extension of Term of Promissory Note - The Manila Times

May 19, 2025

May 19, 2025

Iterum Therapeutics Announces Extension of $20 Million Regulatory Milestone Payment Deadline with Pfizer to 2029 - Nasdaq

May 19, 2025

May 19, 2025

Iterum Gains 3-Year Extension on $20M Pfizer Payment, Strengthens ORLYNVAH Launch Strategy - Stock Titan

May 19, 2025

May 19, 2025

Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026 - MSN

May 19, 2025

May 16, 2025

When Will Iterum Therapeutics plc (NASDAQ:ITRM) Become Profitable? - simplywall.st

May 16, 2025

May 14, 2025

Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025

May 14, 2025

Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... - Yahoo Finance

May 14, 2025

May 14, 2025

Iterum Therapeutics PLC (ITRM) Q1 2025 Earnings Call Highlights: - GuruFocus

May 14, 2025

May 13, 2025

ITRM Plans Fourth-Quarter Launch for ORLYNVAH in UTI Treatment | - GuruFocus

May 13, 2025

May 13, 2025

Iterum Therapeutics (ITRM) Projects Adequate Funding Until 2026 - GuruFocus

May 13, 2025

May 13, 2025

Iterum Therapeutics plc SEC 10-Q Report - TradingView

May 13, 2025

May 13, 2025

Iterum Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times

May 13, 2025

May 13, 2025

Transcript : Iterum Therapeutics plc, Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com

May 13, 2025

May 12, 2025

Q1 Earnings Estimate for ITRM Issued By HC Wainwright - Defense World

May 12, 2025

May 11, 2025

Iterum Therapeutics’ (ITRM) Buy Rating Reiterated at HC Wainwright - Defense World

May 11, 2025

May 10, 2025

Iterum Therapeutics plc (NASDAQ:ITRM): When Will It Breakeven? - Yahoo Finance

May 10, 2025

May 10, 2025

Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Monday - Defense World

May 10, 2025

May 09, 2025

Iterum Therapeutics (ITRM) Receives Buy Rating from HC Wainwrigh - GuruFocus

May 09, 2025

May 09, 2025

Iterum Therapeutics (ITRM) Receives Buy Rating from Analyst | IT - GuruFocus

May 09, 2025

May 06, 2025

Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 - Yahoo Finance

May 06, 2025

May 02, 2025

Renaissance Technologies LLC Purchases Shares of 438,816 Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World

May 02, 2025

May 01, 2025

Check Out Iterum Therapeutics Plc (ITRM)’s Trade Data Rather Than the Analysts’ Views - Sete News

May 01, 2025

May 01, 2025

Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares - The Manila Times

May 01, 2025

Apr 30, 2025

Iterum Therapeutics Raises $5M from Single Investor: Major Push for Antibiotic Commercialization - Stock Titan

Apr 30, 2025

Apr 30, 2025

Iterum Therapeutics Plc: Rising -64.90% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com

Apr 30, 2025

Apr 30, 2025

Iterum Therapeutics Plc (ITRM) Becoming More Attractive for Investors - knoxdaily.com

Apr 30, 2025

Apr 29, 2025

Iterum Therapeutics (ITRM) Secures $5 Million in Direct Offering - GuruFocus

Apr 29, 2025

Apr 29, 2025

Evaluating ITRM’s financial ratios for a profitable investment - uspostnews.com

Apr 29, 2025

Apr 29, 2025

Iterum Therapeutics secures $5 million in direct offering - Investing.com

Apr 29, 2025

Apr 29, 2025

Iterum Therapeutics Announces $5 Million Registered Direct Offering Of Ordinary Shares - marketscreener.com

Apr 29, 2025

Apr 29, 2025

Iterum Therapeutics plc Announces Definitive Agreement for $5 Million Registered Direct Offering of Shares - Nasdaq

Apr 29, 2025

Apr 29, 2025

Iterum Therapeutics Secures Critical $5M Funding: ORLYNVAH Drug Launch Plans Accelerate - Stock Titan

Apr 29, 2025

Apr 24, 2025

ITRM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com

Apr 24, 2025

Apr 24, 2025

Iterum Therapeutics Plc (NASDAQ:ITRM) Shares Surged 24.11% In A Week – But Can It Maintain Its Gains? - Marketing Sentinel

Apr 24, 2025

Apr 14, 2025

Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics - The Manila Times

Apr 14, 2025

Apr 14, 2025

Groundbreaking Research Reveals Age-Specific Patterns in Antibiotic Resistance for UTI Patients - Stock Titan

Apr 14, 2025

Apr 09, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 09, 2025

Apr 07, 2025

What is Iterum Therapeutics Plc (ITRM) Stock Return on Shareholders’ Capital? - Sete News

Apr 07, 2025

Apr 05, 2025

Iterum Therapeutics Plc (ITRM): Significant Improvements, Worth Considering - stocksregister.com

Apr 05, 2025

Mar 27, 2025

Sulopenem Etzadroxil/Probenecid (orlynvah) by Iterum - openPR.com

Mar 27, 2025

Mar 19, 2025

Iterum outlines ORLYNVAH's market potential with exclusivity through 2034 - MSN

Mar 19, 2025

Mar 10, 2025

Iterum Therapeutics appoints Joseph Whalen to its Board By Investing.com - Investing.com Canada

Mar 10, 2025

Mar 10, 2025

Iterum Therapeutics appoints Joseph Whalen to its Board - Investing.com

Mar 10, 2025

Mar 10, 2025

Iterum Therapeutics Appoints New Board Members - TipRanks

Mar 10, 2025

Mar 07, 2025

Sanctuary Advisors LLC Invests $35,000 in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World

Mar 07, 2025